A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Pemetrexed (Primary) ; Trastuzumab-deruxtecan (Primary) ; Volrustomig (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms DL03
- Sponsors AstraZeneca
- 05 Jun 2024 Planned number of patients changed from 168 to 248.
- 24 Oct 2023 Trial design presented at the 48th European Society for Medical Oncology Congress
- 24 Oct 2023 According to Trial design presented at the 48th European Society for Medical Oncology Congress, In part 1 enrollment has been completed. Part 2 of the trial was not initiated.